Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia

Ta, Boon; Ge, Van Venrooij; Eckhardt,

doi:10.1007/s11934-001-0067-z

Cited by 38 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have suggested a specific association between BPH and diabetes. Diabetes is reported to be associated with greater BPH symptom severity [24]. In a large-scale observational study in which 9,856 patients with clinically diagnosed BPH participated, 1,290 (13.1%) were found to be diabetic indicating a pathophysiological link between these two conditions [25].…”

Section: Diabetes Mellitusmentioning

confidence: 99%

“…In a large-scale observational study in which 9,856 patients with clinically diagnosed BPH participated, 1,290 (13.1%) were found to be diabetic indicating a pathophysiological link between these two conditions [25]. Previous studies have shown that men with noninsulindependent diabetes had the highest median annual prostate growth rate compared to those without diabetes [24,26]. A possible explanation for an association between BPH and diabetes may result from the fact that these conditions can cause similar urological symptoms.…”

Section: Diabetes Mellitusmentioning

confidence: 99%

See 1 more Smart Citation

Benign prostatic hyperplasia: dietary and metabolic risk factors

Nandeesha¹

2008

Int Urol Nephrol

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is the most common nonmalignant condition of the prostate occurring in ageing men. Even though BPH is a major public health problem, causing high morbidity and substantial worsening in men's quality of life, little is known about its risk factors. Several studies revealed that it is a multifactorial disease. Previous studies have documented family history, hormonal imbalance, and growth factors as etiological factors in the development of BPH. This review focuses on the dietary and metabolic risk factors including diabetes mellitus, hypertension, obesity, hyperinsulinemia, as well as dyslipidemia and their mechanisms in the pathogenesis of BPH.

show abstract

Section: Diabetes Mellitusmentioning

confidence: 99%

Section: Diabetes Mellitusmentioning

confidence: 99%

Benign prostatic hyperplasia: dietary and metabolic risk factors

Nandeesha¹

2008

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…Diabetic cystopathy symptoms are often errone-ously attributed to BOO. Thus the correct diagnosis of symptoms etiology in diabetic patients with LUTS and BPH is critical for therapeutic success [3,4] . 30-40% of patients with prostate enlargement do not have BOO and, therefore, do not benefit from transurethral resection of the prostate (TURP) [5] .…”

Section: Introductionmentioning

confidence: 99%

Urodynamic Evaluation in Diabetic Patients with Prostate Enlargement and Lower Urinary Tract Symptoms

et al. 2008

View full text Add to dashboard Cite

Introduction: Lower urinary tract symptoms (LUTS) are common in men over 50 years of age due to prostate enlargement. Diabetes mellitus is also more prevalent in this group. LUTS may result from bladder outlet obstruction (BOO) secondary to prostate enlargement or bladder dysfunction secondary to diabetes or even from a combination of both. Objectives: The objective of this study was to determine the prevalence of BOO and other urodynamic abnormalities in diabetic patients with LUTS and enlarged prostate. A secondary objective was to assess the predictive value of non-invasive tests for BOO diagnosis in this group of patients. Patients and Methods: 50 consecutive diabetic patients with enlarged prostate and LUTS were evaluated by the International Prostate Symptom Score (IPSS), ultrasonography and urodynamics. BOO diagnosis was based on pressure/flow measurements according to the International Continence Society’s standards. Results: Of the 50 patients in the study, 23 (46%) had BOO. There was no correlation between the IPSS, uroflowmetry, post-voiding residual urine or prostate volume and the presence of BOO (p > 0.05). Conclusions: There is a relatively low prevalence of BOO in diabetic patients with prostate enlargement and LUTS. Non-invasive tests did not allow the identification of these subjects. Only urodynamic evaluation is able to determine symptom etiology.

show abstract

“…In a recently published study using a cell culture model of human prostatic stromal cells, it was shown that prostatic stromal cells respond to hypoxia by upregulation of secretion of several growth factors in vitro suggesting that hypoxia may trigger prostatic growth [3]. Hypoxia in the prostate may occur in patients who present with generalised or localised vascular damage, and indeed several studies have suggested an association between the presence of vascular disorders such as coronary heart disease or diabetes mellitus and prostatic disease [4][5][6][7]. The earliest report that discusses the association of diabetes mellitus with vascular degenerative complications goes back to the early 1950s [8].…”

Section: Introductionmentioning

confidence: 99%

Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia

et al. 2005

View full text Add to dashboard Cite

Aims/hypothesis: The aim of this study was to evaluate the relationship between benign prostatic hyperplasia (BPH) and arteriosclerosis shown in a model of type 2 diabetes in a trans-sectional population study using contrast-enhanced colour Doppler ultrasound for exact assessment of prostatic blood flow. Methods: Contrast-enhanced transrectal colour Doppler ultrasound was performed using a microbubble-based ultrasound enhancer SonoVue for evaluating prostate vascularity (transitional zone [TZ] and peripheral zone [PZ]) in diabetic BPH patients, non-diabetic BPH patients and healthy subjects. Computer-assisted quantification of colour pixel intensity (CPI) was used to objectively evaluate the prostate vascularity. Resistive index measurements were obtained in the TZ and the PZ. Findings were compared between these three groups. Results: TZ-CPI was significantly lower in diabetic patients than in non-diabetic BPH men (p=0.001), whereas the CPI of the PZ showed no difference between these two groups (p=0.978). TZ-CPI of patients with diabetic and non-diabetic BPH were significantly lower than in controls (p<0.001), but no difference was found between diabetic and healthy patients in the PZ (p=0.022) and borderline significance was seen when comparing patients of the BPH group with the control patients (p=0.019). Resistive index values of the TZ in diabetic patients showed significantly higher values (p<0.001) than the BPH and control groups. Conclusions/interpretation: The significantly lower CPI and higher resistive index values of the TZ in diabetic patients compared with patients with nondiabetic BPH and healthy subjects indicate considerable vascular damage in the TZ of these patients. Diabetic vascular damage may cause hypoxia and may contribute to the pathogenesis of BPH.

show abstract

Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia

Cited by 38 publications

References 12 publications

Benign prostatic hyperplasia: dietary and metabolic risk factors

Benign prostatic hyperplasia: dietary and metabolic risk factors

Urodynamic Evaluation in Diabetic Patients with Prostate Enlargement and Lower Urinary Tract Symptoms

Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia

Contact Info

Product

Resources

About